Literature DB >> 17057193

Novel signal transduction pathways: analysis of STAT-3 and Rac-1 signaling in inflammatory bowel disease.

R Atreya1, I Atreya, M F Neurath.   

Abstract

Although the precise etiology of inflammatory bowel disease still remains unclear, considerable progress has been made in the identification of novel signal transduction pathways that elucidate the immunopathogenesis involved in the perpetuation of the inflammatory process. Augmented T cell resistance against apoptosis is regarded as a pivotal factor in the pathogenesis, as it impairs mucosal homeostasis and leads to unrestrained accumulation of activated T cells, which subsequently lead to the amplification of the inflammatory response. Therefore novel therapeutic strategies aim at restoring mucosal T cell susceptibility to apoptosis through targeting of signal transduction pathways that are elemental for augmented resistance of T lymphocytes against apoptosis. For example, a newly developed humanized anti-IL-6R monoclonal antibody that induces intestinal T cell apoptosis showed clinical efficacy in patients with active Crohn;s disease. Moreover, recent data that relate the immunosuppressive effects of azathioprine in inflammatory bowel disease to its apoptosis-inducing potential, have important implications for the design of a more specific therapeutic approach. The examination of these novel signal transduction pathways has elucidated the pathogenetic mechanisms involved in inflammatory bowel disease and gives hope for the development of new strategies that may result in a more effective and less toxic therapeutic procedure.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17057193     DOI: 10.1196/annals.1326.001

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  8 in total

1.  Transcription factors NRF2 and NF-κB are coordinated effectors of the Rho family, GTP-binding protein RAC1 during inflammation.

Authors:  Antonio Cuadrado; Zaira Martín-Moldes; Jianping Ye; Isabel Lastres-Becker
Journal:  J Biol Chem       Date:  2014-04-22       Impact factor: 5.157

Review 2.  Disruption of inflammatory signals by cytokine-targeted therapies for inflammatory bowel diseases.

Authors:  Flavio Caprioli; Roberta Caruso; Massimiliano Sarra; Francesco Pallone; Giovanni Monteleone
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

3.  Orally administered emu oil attenuates disease in a mouse model of Crohn's-like colitis.

Authors:  Chloe J Mitchell; Gordon S Howarth; Lauren C Chartier; Debbie Trinder; Ian C Lawrance; Li San Huang; Suzanne Mashtoub
Journal:  Exp Biol Med (Maywood)       Date:  2020-09-09

Review 4.  Use of thiopurines in inflammatory bowel disease: Safety issues.

Authors:  Anastasia Konidari; Wael El Matary
Journal:  World J Gastrointest Pharmacol Ther       Date:  2014-05-06

5.  Structural basis of guanine nucleotide exchange mediated by the T-cell essential Vav1.

Authors:  Jill E Chrencik; Alexei Brooun; Hui Zhang; Irimpan I Mathews; Greg L Hura; Scott A Foster; J Jefferson P Perry; Markus Streiff; Paul Ramage; Hans Widmer; Gary M Bokoch; John A Tainer; Gisbert Weckbecker; Peter Kuhn
Journal:  J Mol Biol       Date:  2008-05-17       Impact factor: 5.469

Review 6.  Prevention of colitis-associated cancer: natural compounds that target the IL-6 soluble receptor.

Authors:  Cate Moriasi; Dharmalingam Subramaniam; Shanjana Awasthi; Satish Ramalingam; Shrikant Anant
Journal:  Anticancer Agents Med Chem       Date:  2012-12       Impact factor: 2.505

7.  Protective effect of aqueous extract of Oroxylum indicum Linn. (root bark) against DNBS-induced colitis in rats.

Authors:  Shrikant V Joshi; Bhavin A Vyas; Payal D Shah; Dinesh R Shah; Shailesh A Shah; Tejal R Gandhi
Journal:  Indian J Pharmacol       Date:  2011-11       Impact factor: 1.200

Review 8.  Wnt and Rho GTPase signaling in osteoarthritis development and intervention: implications for diagnosis and therapy.

Authors:  Shouan Zhu; Huanhuan Liu; Yan Wu; Boon Chin Heng; Pengfei Chen; Hua Liu; Hong Wei Ouyang
Journal:  Arthritis Res Ther       Date:  2013-07-11       Impact factor: 5.156

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.